Abstract
Cardiac sympathetic upregulation is one of the neurohormonal compensation mechanisms that play an important role in the pathogenesis of chronic heart failure (CHF). In the past decades, cardiac123 I-mIBG scintigraphy has been established as a feasible technique to evaluate the global and regional cardiac sympathetic innervation. Although cardiac123 I-mIBG imaging has been studied in many cardiac and neurological diseases, it has extensively been studied in ischemic and non-ischemic CHF. Therefore, this review will focus on the role of123 I-mIBG imaging in CHF. This non-invasive, widely available technique has been established to evaluate the prognosis in CHF. Standardiza-tion, especially among various combinations of gamma camera and collimator, is important for identifying appropriate thresholds for adequate risk stratification. Interestingly, in contrast to the linear relationship between123 I-mIBG-derived parameters and overall prognosis, there seems to be a “bell-shape” curve for123 I-mIBG-derived parameters in relation to ventricular arrhythmia or appropriate implantable cardioverter defibrillator (ICD) therapy in patients with ischemic CHF. In addition, there is a potential clinical role for cardiac123 I-mIBG imaging in optimizing patient selection for implantation of expensive devices such as ICD and cardiac resynchronization therapy (CRT). Based on cardiac123 I-mIBG data risk models and machine learning, models have been developed for appropriate risk assessment in CHF.
Original language | English |
---|---|
Article number | 656 |
Journal | Pharmaceuticals |
Volume | 15 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Jun 2022 |
Keywords
- I-mIBG scintigraphy
- chronic heart failure
- heart-to-mediastinum ratio
- innervation